ABSTRACT chimeric murine models to evaluate the in vivo efficacy, safety, and stability of treatment with β hu -β 654 iPSCs (β 654
Introduction
The thalassemias are a collection of congenital hemolytic anemias caused by aberrant globin-chain production, with at least 60,000 severely affected subjects born worldwide every year. In particular, there are over 40,000 annual births for β-thalassemias, and about 50% occur in Southeast Asia, as estimated by the World Health Organization. 1 Over the last decades, the birth rate of affected children in some areas of Middle Eastern, Southern and Southeast Asia has continued to increase. 2 Prenatal diagnosis may effectively reduce the number of births with this genetic disease; however, this is not possible in some developing countries. Babies with the severe forms of thalassemia can now survive but require much medical intervention, resulting in a rising global healthcare burden. 3 In China, β 654 thalassemia is the most common form, and represents approximately one-fifth of total β-thalassemia cases. It is caused by a C→T substitution at nucleotide 654 of intron 2 (β IVS-2-654) in the β-globin gene, leading to an incorrectly spliced RNA isoform that produces trace amounts of a poorly functioning polypeptide. 4, 5 The resulting imbalance of a-globin with β-globin results in the precipitation of excess free a-chains around the erythrocyte membrane, 4 leading to intramedullary destruction of the erythroid precursors, and a syndrome of ineffective erythropoiesis. 6, 7 As a result, these patients are presented with severe anemia, with abnormal hematologic indices, including lowered red blood cells (RBC), hemoglobin (Hgb) and mean corpuscular hemoglobin concentration (MCHC), etc. Splenomegaly and hepatomegaly related to significant extramedullary hematopoiesis (EMH), as well as iron deposits in multi-organs are typically observed.
Previous attempts to correct the underlying molecular mechanisms have been reported. For example, the transduction of an extra copy of the normal human β-globin gene into allogenic hematopoietic stem cells was first demonstrated by May et al. 8, 9 The transgenic human β-globin approach, combined with RNAi and anti-sense RNA against a-globin leading to partial reversion of anemia phenotypes, was also verified in mouse model systems. 10, 11 However, these treatment options still largely fall into the domain of basic research. In clinical therapy, β-thalassemia patients mostly rely on lifelong blood transfusions combined with iron chelation. 12, 13 Recently, therapeutic treatment using splenectomy has been introduced to decrease blood consumption and iron intake. 14, 15 Hematopoietic stem cell or cord blood transplantation are also used as a strategy for partially relieving the symptoms. [16] [17] [18] However, resources for finding matched bone marrow donors are limited. All of the aforementioned therapies are expensive and can be painful procedures. With the development of stem cell induction techniques, 19 induced pluripotent stem cells (iPSCs) potentially represent an excellent approach to treat genetic hematopathies after birth. 20 Although β-thalassemia is one of the most common human genetic diseases, there is still no effective treatment other than bone marrow transplantation. Induced pluripotent stem cells have been considered good candidates for the future repair or replacement of malfunctioning organs. As a basis for developing transgenic induced pluripotent stem cell therapies for thalassemia, β 654 induced pluripotent stem cells from a β 654 -thalassemia mouse transduced with the normal human β-globin gene, and the induced pluripotent stem cells with an erythroid-expressing reporter GFP were used to produce chimeric mice. Using these chimera models, we investigated changes in various pathological indices including hematologic parameters and tissue pathology. Our data showed that when the chimerism of β 654 induced pluripotent stem cells with the normal human β-globin gene in β 654 mice is over 30%, the pathology of anemia appeared to be reversed, while chimerism ranging from 8% to 16% provided little improvement in the typical β-thalassemia phenotype. Effective alleviation of thalassemia-related phenotypes was observed when chimerism with the induced pluripotent stem cells owning the erythroid-expressing reporter GFP in β 654 mouse was greater than 10%. Thus, 10% or more expression of the exogenous normal β-globin gene reduces the degree of anemia in our β-thalassemia mouse model, whereas treatment with β 654 induced pluripotent stem cells which had the normal human β-globin gene had stable therapeutic effects but in a more dose-dependent manner.
Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia mice transduced with the human β-globin gene), and compared this to treatment with non-transgenic HG-iPSCs.
Methods
The β 654 mice 21 and HG mice were used to generate β 654 iPSCs and HG-iPSCs carrying defective or wild-type β-globin genes, respectively. Following the generation of β 654 iPSCs derived from tail tip fibroblasts (TTF) of β 654 mice with methods previously described, 22 a wild-type human β-globin gene was introduced into the β 654 iPSCs using a lentiviral vector (hBG) (resulting in β hu -β 654 iPSCs). β hu -β 654 iPSCs or HG-iPSCs were then injected into the blastocytes of wild-type (WT) or β 654 mice. These blastocytes were transferred into the uteri of 2.5 days post coitus (dpc) pseudo-pregnant WT mice (ICR strain), which gave birth to chimeric pups at approximately 20 dpc. 23 Expression of human β-globin was detected by RT-PCR and Western blot analysis. Hematologic parameters were determined using the Hematology Analyzer (KX-21, Sysmex, Japan). The peripheral blood smears and bone marrow slides were stained with Wright-Giemsa (BASO BA4017, Zhuhai, China) or brilliant tar blue (BASO BA4003, Zhuhai, China). The tissue sections, including spleens and livers, were stained with hematoxylin-eosin (BASO BA4025, Zhuhai, China) or Pearl's Prussian blue (BASO BA4089B, Zhuhai, China). Quantitative PCR was performed using primers for Tfr1, Twsg1, and Gdf15 to analyze EMH in the spleens, and with Bmp6 primers to evaluate iron accumulation in the livers. All primer pairs are listed in Online Supplementary Table S1 . The mouse serum soluble transferrin receptor (sTfR) level was determined with ELISA (AMEKO, Shanghai, China).
Additional study methods and analyses are provided in the Online Supplementary Appendix.
The strain of wild-type (WT) mice used in this study was ICR. In transgenic HS23-GFP mice (HG), the erythroid-expressing GFP was driven by the human β-globin promoter. The study used β 654 thalassemia mice with a copy of the human β 654 globin gene 21 
Results

Production of chimeric mice
Production of β 654 iPSCs and HG-iPSCs was confirmed by PCR analysis of transgene expression (Online Supplementary Appendix and Online Supplementary Figure  S1 ). After the β 654 iPSCs were transduced with a human β-globin gene, five β 654 iPS cell lines were screened using PCR for long terminal repeat (LTR) sequence in vector, three of which were shown to be positive for β 
Improvement of hematologic indices in chimeras
Erythrocytes from two different sources co-existed in the same blood smears of HG↔β 654 mice ( Figure 2C ), indicating that the iPSCs had differentiated into erythrocytes in the chimeric mice. HG-iPSCs could differentiate into GFP erythrocytes in HG↔β 654 mice ( Figure 2D ), and the GFP expressing erythrocytes derived from HG-iPSCs had normal morphology, with biconcave-discoid shape and even pigmentation, while the cells without GFP expression (originated from β 654 blastocysts) had morphology typical of β-thalassemia ( Figure 2C ). As expected, β centage of chimerism ( Figure 2B and 2G). These results indicated that the exogenous human β-globin played an important role in balancing the ratio of a-globin and β-globin. 654 mice with higher levels of chimerism (> 30%) showed fewer poikilocytes, target cells, and reticulocytes in their blood smears, and a smaller proportion of nucleated cells were found in their bone marrow, when compared to mice with lower levels of chimerism (<30%) (Online Supplementary Figure  S3A-C) . Thus, the hematopoietic disorder of β hu -β 654 ↔β 654 mice appeared to be improved when the chimerism reached a certain proportion (Figure 3A-C) . On the other hand, disease symptoms such as fewer reticulocytes, diseased anisocytosis, poikilocytosis and number of target cells were reduced in HG↔β 654 mice regardless of the level of chimerism (Figure 3A-C) .
sTfR (soluble transferrin receptor) expression can sometimes be used to indicate levels of compensatory erythropoiesis, as its serum level rises when erythropoiesis increases in the cases of autoimmune hemolytic anemia, hereditary spherocytosis, and thalassemia. [24] [25] [26] [27] [28] [29] The sTfR expression levels are found to be normal in β Figure S4A) , suggesting improved erythropoiesis in the chimeras.
Histopathological changes in spleens and livers of chimeras
The histopathology of spleens in β 654 mice displayed a significant expansion of red pulp, a dense occupation of nucleated erythroid precursors, and a relative decrease in white pulp, and the marginal zones were obscured by a large number of nucleated RBCs (Figure 3D and E) . However, in the β hu -β 654 ↔β 654 mice and the HG↔β 654 mice, the amount of red pulp was considerably decreased and the marginal zones became visible ( Figure 3D and E) ; the state of the splenomegaly was also improved (Figure 4A-C) . Figure S4B ). This also confirmed that the hemosiderin was reduced in β hu -β 654 ↔β 654 mice. Extramedullary hematopoiesis (EMH) was examined in the chimeric models. The regression of EMH was assessed by morphological examination of spleens and livers from 10-week old chimeras. The number of nucleated erythroid precursors in red pulp was reduced ( Figure 3D and E), other immature hematopoietic cells such as megakaryocytes ( Figure 3E , yellow arrows) in spleens and erythroid precursors ( Figure 3H , white arrow) in livers were also much reduced in the chimeras.
To further characterize changes in the level of EMH, selected relevant genes were analyzed in detail. Twsg1, Gdf15, and Tfr1 are markers of ineffective erythropoiesis, 33 and these markers had higher expression in the spleens of 
Effect of different chimerism levels on thalassemia phenotypes
The above results illustrated that anemia symptoms were ameliorated in β hu -β 654 ↔β 654 mice. To determine whether pathology reversal is influenced by the level of chimerism, β Figure S6D) . Figure 5A and B), but Gdf15 levels showed no statistically significant differences (P>0.05) ( Figure 5C ). This suggests gradual improvements of EMH with increasing levels of iPSC chimerism, with highest chimerism producing full control of spleen EMH in the β 
Discussion
In 2007, one year after the first successful induction of pluripotent stem cells from adult cells, Hanna et al. demonstrated that iPSCs could be used therapeutically in treating sickle cell anemia in a mouse model. 20 We have previously generated viable mice from iPSCs via tetraploid compensation, 34 confirming the totipotency of iPSCs. These results support the strategy of using iPSCs from normal donors, or corrected iPSCs from the patient's own differentiated cells, for potential treatment of a variety of genetic diseases.
Successful treatment of β-thalassemia based on the transplantation of genetically modified autologous hematopoietic cells using lentiviral vectors set the stage for its use in clinical applications, 35 and Cavazzano et al. reported one effective case in their Phase I/II clinical trial study. 36 However, several recently published reports showed that these approaches remain inefficient. 8, [37] [38] [39] Therapies using iPSCs combined with a transgene (or transgenes) can potentially cure thalassemia in the future, but issues including efficacy, safety and stability of the cells must be resolved.
In current clinical practice, a state of mixed chimerism of host-and donor-derived cells is detected early after transplantation and often progresses towards complete chimerism after hematopoietic stem cell transplantation (HSCT) for thalassemia, but some patients would remain in a mixed chimeric state for a long period of time after HSCT state. [40] [41] [42] [43] [44] This implies that thalassemia can be relieved with appropriate doses of hematopoietic stem cells. Marco et al. found that most of the erythrocytes detected were derived from small proportions of donorengrafted cells in the allogeneic HSCT patients. 44 Thus, it is important to study the dose-effect of stem cells/iPSCs in treating these diseases. As stem cells (including iPSCs) in chimeras were shown to display sustainable structural and functional integrity, our iPSC-chimeric model provides a unique platform to study the in vivo physiology and therapeutic effect of iPSCs following one life course. [45] [46] [47] The iPSCs used could avoid immunological rejection, and this is valuable for studying the dose-thresholds of iPSCs needed for treating thalassemia under normal physiological state without immunological suppression. In our study, we used the classic approach of gene therapy to transfer normal human β-globin into β 654 iPSCs and then used these modified β hu -β 654 iPSCs to generate chimeras; chimeras of HG-iPSCs were also generated (Online Supplementary Table  S2 654 chimeras still had the thalassemia phenotype; however, when the chimerism exceeded 30%, anemia was controlled effectively in these chimeras.
Our results showed that the pathology of thalassemia was alleviated by β hu -β 654 iPSCs and HG-iPSCs, and no other abnormal symptoms occurred in these chimeras. The therapeutic effect seemed stable. Although this model system might not be translated directly into human therapy, it is a very important animal model for treatment of genetic diseases. It provides vital information for the development of prenatal and postnatal iPSC therapies in these patients. Our previous work demonstrated the feasibility of generating chimera (exceeding 30% of chimerism) through intrauterine transplantation of hematopoietic stem cells. 48 This could provide a model system for prenatal therapy using iPSCs to treat thalassemia fetuses. On the other hand, effective post-natal therapy with autologous modified iPSCs may require engineered expression of normal β-globin and chimerism levels that exceed 20%.
The results of our study provide useful base-line data for developing clinical iPSC treatments for β 654 thalassemia, the most common form of β-thalassemia in China. β-thalassemia has different genotypes, which may or may not be correlated to the degree of the disease severity. 49 For example, patients with IVSI-6 mutation of β-globin in the homozygous state have slightly increased HbF and are not transfusion dependent; 50 but Gringras et al. found that the patient compound heterozygous β 0 /β ++ with C-T substitution at nucleotide position -101 in the promoter region of the β-globin started transfusion as early as the age of four years. 49 These clinical treatments according to different types of β-thalassemia inferred that effective therapeutic dose of iPSCs should be carefully developed and studied. In the future, other types of β-thalassemia will be used for the study of effective iPSC therapies with or without genetic Therapeutic iPS chimerism in β-thalassemia mice haematologica | 2014; 99 (8) modification of patients' iPSCs, and this will no doubt have a positive impact on the use of iPSCs in clinical applications.
